Cost of illness of Primary Biliary Cholangitis - a population-based study
| Autor: | Marzia Bonfanti, Umberto Restelli, Marco Carbone, Pietro Invernizzi, Alessio Gerussi, Davide Croce |
|---|---|
| Přispěvatelé: | Gerussi, A, Restelli, U, Croce, D, Bonfanti, M, Invernizzi, P, Carbone, M |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Cirrhosis medicine.medical_treatment Liver transplantation SECS-P/06 - ECONOMIA APPLICATA 03 medical and health sciences Health services Indirect costs 0302 clinical medicine Cost of Illness MED/12 - GASTROENTEROLOGIA medicine Cost of illness Humans Cost-of-illne Aged Hepatology Adult patients business.industry Liver Cirrhosis Biliary Cholangiopathie Gastroenterology Middle Aged medicine.disease Liver Transplantation Population based study Hospitalization Italy Liver 030220 oncology & carcinogenesis Emergency medicine 030211 gastroenterology & hepatology Female Population-based studie MED/09 - MEDICINA INTERNA business Medical costs Rare disease |
| Popis: | Background The economic burden of Primary Biliary Cholangitis (PBC) has not been investigated at population-level. Aim of this study was to estimate the cost of illness of PBC in Lombardy, Italy. Methods Individuals with PBC were identified through ICD-9-CM code 571.6 and/or medical exemption code 008.571.6, from the Banca Dati Assistito of Lombardy. Only health services (outpatient, inpatient activities and drugs) related to PBC were considered to estimate direct medical costs in 2017. Results We identified 970 adult patients (83.5% females) with a mean age of 61 years. Global annual costs were equal to € 913,763 (€ 942 per patient), with € 459,506 (50.3%, € 474 per patient) deriving from hospitalizations (mostly due to liver transplantation, 30.5%, and cirrhosis complications, 20.6%). Costs from outpatient activities were € 109,090 (11.9%, € 112 per patient). Conclusions This study provides an overview of the costs attributed to PBC care and management, mainly related to hospitalizations for cirrhosis complications, which is necessary for assuring cost-effective introduction of novel therapies. Additional studies focused on indirect cost, e.g. overall loss of productivity, are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|